(Press-News.org) Cardiovascular disease results in around 20 million deaths worldwide and causes around a quarter of all deaths in the UK. Statins are highly effective drugs that lower LDL (“bad”) cholesterol levels and have been repeatedly proven to reduce the risk of cardiovascular disease. However, there have been concerns about possible side effects.
The researchers gathered data from 23 large-scale randomised studies from the Cholesterol Treatment Trialists’ Collaboration: 123,940 participants in 19 large-scale clinical trials comparing the effects of statin therapies against a placebo (or dummy tablet), and 30,724 participants in four trials comparing more intensive versus less intensive statin therapy.
They found similar numbers of reports for those taking the statins and those taking the placebo for almost all the conditions listed in package leaflets as possible side effects. For example, each year, the number of reports of cognitive or memory impairment was 0.2% in those taking the statins, but also 0.2% in those taking the placebo. This means that while people may notice these problems whilst taking statins, there is no good evidence that they are caused by the statin.
Key findings:
• There was no statistically significant excess risk from statin therapy for almost all the conditions listed in package leaflets as potential side effects.
• Taking a statin did not cause any meaningful excess of memory loss or dementia, depression, sleep disturbance, erectile dysfunction, weight gain, nausea, fatigue or headache, and many other conditions.
• There was a small increase in risk (about 0.1%) for liver blood test abnormalities. However, there was no increase in liver disease such as hepatitis or liver failure, indicating that the liver blood test changes do not typically lead to more serious liver problems.*
Christina Reith, Associate Professor at Oxford Population Health and lead author of the study, said ‘Statins are life-saving drugs used by hundreds of millions of people over the past 30 years. However, concerns about the safety of statins have deterred many people who are at risk of severe disability or death from a heart attack or stroke. Our study provides reassurance that, for most people, the risk of side effects is greatly outweighed by the benefits of statins.’
Previous work by the same researchers established that most muscle symptoms are not caused by statins; statin therapy caused muscle symptoms in only 1% of people during the first year of treatment with no excess thereafter. It has also shown that statins can cause a small increase in blood sugar levels, so people already at high risk may develop diabetes sooner.
Professor Bryan Williams, Chief Scientific and Medical Officer at the British Heart Foundation, said ‘These findings are hugely important and provide authoritative, evidence-based reassurance for patients. Statins are lifesaving drugs, which have been proven to protect against heart attacks and strokes. Among the large number of patients assessed in this well-conducted analysis, only four side effects out of 66 were found to have any association with taking statins, and only in a very small proportion of patients.
‘This evidence is a much-needed counter to the misinformation around statins and should help prevent unnecessary deaths from cardiovascular disease. Recognising which side effects might genuinely be associated with statins is also important as it will help doctors make decisions about when to use alternative treatments.’
Professor Sir Rory Collins, Emeritus Professor of Medicine and Epidemiology at Oxford Population Health and senior author of the paper said ‘Statin product labels list certain adverse health outcomes as potential treatment-related effects based mainly on information from non-randomised studies which may be subject to bias. We brought together all of the information from large randomised trials to assess the evidence reliably. Now that we know that statins do not cause the majority of side effects listed in package leaflets, statin information requires rapid revision to help patients and doctors make better-informed health decisions.’
All of the trials included in the analyses were large-scale (involving at least 1,000 participants) and tracked patient outcomes for a median of nearly five years. The trials were double-blind, meaning that neither the trial participants nor those managing the participants or leading the study knew who was receiving which treatment, to avoid potential biases due to knowledge of treatment allocation. The list of possible side effects was compiled from those listed for the five most commonly prescribed statins.
The study was conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration, a joint initiative coordinated between the Clinical Trial Service Unit & Epidemiological Studies Unit, Oxford Population Health, and the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia, on behalf of academic researchers representing major statin trials worldwide.
The work was funded by the British Heart Foundation, UKRI Medical Research Council, and the Australian National Health and Medical Research Council. The work of the CTT is overseen by an Independent Oversight Panel.
ENDS
Notes to editors:
*There were also very small increases in risk (less than 0.1%) for medical issues that involved changes in urine, and oedema (a build-up of fluid in the body typically causing swelling in the ankles, feet and legs) in the trials of statin versus placebo, but analysis of the four trials of more intensive versus less intensive statin therapy showed no significant excess risk for these changes, suggesting these excesses were not real.
There is an embargoed UK Science Media Centre press briefing on this study at 10:30 GMT on Tuesday 3 February. Please contact fiona@sciencemediacentre.org if you would like to attend or to receive the recording.
Post-publication link: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01578-8/fulltext
For further information, interview requests, or to request a pre-publication copy of the manuscript, please contact Lulu Phillips, Senior Communications Officer at Oxford Population Health, louise.phillips@ndph.ox.ac.uk / +44 (0) 1865 617824 or Anne Whitehouse, Director of Communications and Public Engagement, Oxford Population Health, anne.whitehouse@ndph.ox.ac.uk / +44 (0) 1865 289474.
For further information on the methods used in this study, see: Cholesterol Treatment Trialists’ Collaboration. Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. Clinical Trials. 2022;19(6):593-604. doi:10.1177/17407745221105509.
About the Cholesterol Treatment Trialists’ Collaboration
The Cholesterol Treatment Trialists’ (CTT) Collaboration was established in 1994, with its initial protocol being published in 1995. It was set up after it was recognised that no single lipid intervention trial would be likely to have a sufficient number of trial participants (and hence statistical power) to reliably assess mortality outcomes or look at events in particular types of patient. It conducts meta-analyses of large-scale (at least 1,000 participants), long-term (at least two years scheduled treatment duration) un-confounded, randomised controlled trials of lipid intervention therapies.
The collaboration involves approximately 150 doctors, statisticians and research scientists, including experts in the field of cardiology, epidemiology, lipidology and clinical trials, from across the world. Although individual trials that are contributing data to the analyses were funded by the pharmaceutical industry, as well as by charities and government organisations, the CTT Collaboration has not received grant funding from industry.
About Oxford Population Health
Oxford Population Health (the Nuffield Department of Population Health) is a world-leading research institute, based at the University of Oxford, which investigates the causes and prevention of disease. Oxford Population Health brings together a number of world-leading research groups, including the Clinical Trial Service Unit and Epidemiological Studies Unit and other groups working on cancer epidemiology, demographic science, health economics, ethics, and health record linkage. It is also the lead partner in the Oxford University Big Data Institute.
END
Statins do not cause the majority of side effects listed in package leaflets
2026-02-06
ELSE PRESS RELEASES FROM THIS DATE:
UC Riverside doctoral student awarded prestigious DOE fellowship
2026-02-05
RIVERSIDE, Calif. -- Ryan Milton, a fourth-year doctoral student in nuclear physics at UC Riverside, has been awarded a U.S. Department of Energy’s Office of Science Graduate Student Research (SCGSR) Fellowship. The fellowship, which provides a $3,600 monthly stipend for one year, will support his research at the SLAC National Accelerator Laboratory, part of Stanford University.
“My research focuses on developing and deploying AI tools to understand the behavior of protons and neutrons in nuclei,” Milton said. “Each proton and neutron is made of quarks, but we still don’t fully understand ...
UMD team finds E. coli, other pathogens in Potomac River after sewage spill
2026-02-05
COLLEGE PARK, Md. – Following one of the largest sewage spills in U.S. history, University of Maryland researchers have detected high levels of fecal-related bacteria and disease-causing pathogens in the Potomac River, raising urgent public health concerns and underscoring the risks posed by aging sewer infrastructure.
Water sample results collected at the site by researchers show high levels of E. coli are present along with Staphylococcus aureus (the bacteria that causes Staph infections). An antibiotic-resistant strain of S. aureus, MRSA, was also identified at the site of the sewage overflow.
“People coming into contact with the impacted ...
New vaccine platform promotes rare protective B cells
2026-02-05
Cambridge, MA – A longstanding goal of immunotherapies and vaccine research is to induce antibodies in humans that neutralize deadly viruses such as HIV and influenza. Of particular interest are antibodies that are “broadly neutralizing,” meaning they can in principle eliminate multiple strains of a virus such as HIV, which mutates rapidly to evade the human immune system.
Researchers at MIT and the Scripps Research Institute have now developed a vaccine that generates a significant population of rare precursor B cells that are capable of evolving to produce broadly neutralizing antibodies. Expanding these cells is the first step toward a successful HIV ...
Apes share human ability to imagine
2026-02-05
In a series of tea party-like experiments, Johns Hopkins University researchers demonstrate for the first time that apes can use their imagination and play pretend, an ability thought to be uniquely human.
Consistently and robustly across three experiments, one bonobo engaged with cups of imaginary juice and bowls of pretend grapes, challenging long-held assumptions about the abilities of animals.
The findings suggest that the capacity to understand pretend objects is within the cognitive potential of, at least, an enculturated ape, and likely dates back 6 to 9 million years, to our common evolutionary ...
Major step toward a quantum-secure internet demonstrated over city-scale distance
2026-02-05
Marking a significant step toward a quantum-secure internet, researchers have demonstrated device-independent quantum key distribution over optical fibers spanning 100 kilometers (km). The findings show that cryptographic security can be guaranteed with this method, at the metropolitan scale – which represents a much greater distance than previous efforts – and help to close the gap between proof-of-principle quantum network experiments and real-world applications. Quantum key distribution (QKD) is a leading application of quantum technologies, enabling ultra-secure digital communications. Early forms of QKD derive security using trusted ...
Increasing toxicity trends impede progress in global pesticide reduction commitments
2026-02-05
Around the world, the total toxicity and ecological harm from agricultural pesticides are rising, despite recent United Nations commitments to halve pesticide use and risks by 2030. The findings establish a global, toxicity-weighted baseline for pesticide use and identify a subset of pesticides, crops, and countries driving the most biodiversity impacts. The widespread use of agricultural pesticides is a growing threat to global biodiversity. To address this concern, the 15th United Nations Biodiversity Conference set the goal of halving pesticide use and risk by 2030 and recently adopted a new global indicator – total applied toxicity (TAT) – that captures not just ...
Methane jump wasn’t just emissions — the atmosphere (temporarily) stopped breaking it down
2026-02-05
A temporary weakening of the atmosphere’s chemical capacity to break down methane, combined with elevated emissions from tropical wetlands, drove the sharp increase in atmospheric methane observed in 2020 to 2021, according to a new study. Methane (CH4) is a significant contributor to atmospheric warming. In the early 2020s, the amount of atmospheric CH4 grew faster than ever before observed, peaking at 16.2 parts per billion per year (ppb yr-1), before declining to 8.6 ppb yr-1 in 2023. It’s hypothesized that this surge was driven by a combination of increased natural emissions and a coincident decrease in the atmosphere’s oxidizing capacity, namely, fewer OH ...
Flexible governance for biological data is needed to reduce AI’s biosecurity risks
2026-02-05
In a Policy Forum, Doni Bloomfield and colleagues discuss the need for expanded – yet tailored and flexible – governance for the biological data used to develop powerful artificial intelligence (AI) models. Rapidly advancing AI systems trained on biological data have enabled researchers to design new molecules, predict protein structure and function, and probe vast and highly complex biological datasets for novel insights that could greatly expand our understanding of nature and human health. However, these same tools could also be misused for dangerous purposes, such as designing harmful pathogens or generating genetic ...
Increasing pesticide toxicity threatens UN goal of global biodiversity protection by 2030
2026-02-05
At the 15th UN Biodiversity Conference (COP15) in Montreal, Canada, in 2022, nations committed to reducing the risks associated with pesticide use in agriculture by 50% by 2030. A new study by a research team from RPTUKaiserslautern-Landau, published in the journal Science, reveals that this global target is now under serious threat. Using a novel analytical method, the researchers assessed trends in pesticide toxicity worldwide and found that current trajectories fall far short of the 2030 goal. The study concludes that immediate, coordinated ...
How “invisible” vaccine scaffolding boosts HIV immune response
2026-02-05
LA JOLLA, CA—One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein scaffolding that mimics a virus. Then, a person’s immune system produces a range of antibodies that recognize different bits of those proteins. Often, however, some of those antibodies react not to HIV itself—but to the scaffold used to deliver the vaccine.
Now, researchers at Scripps Research and the Massachusetts Institute of Technology (MIT) have developed a new kind ...